Jean-Baptiste Davion

发表

Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis

S. Quijano-roy, C. Barnérias, I. Desguerre, 2022, Neurology.

Anti-pan-neurofascin IgM in COVID-19-related Guillain-Barré syndrome: Evidence for a nodo-paranodopathy

L. Defebvre, F. Cassim, A. Delval, 2020, Neurophysiologie Clinique.

Motor neuron pathology in CANVAS due to RFC1 expansions.

B. Gaymard, D. Grabli, A. Durr, 2021, Brain : a journal of neurology.

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

G. Comi, S. Corti, E. Mazzone, 2022, The Lancet Neurology.

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

M. Tarnopolsky, Y. Chien, J. Charrow, 2021, The Lancet Neurology.

Relation between retina, cognition and brain volumes in MS: a consequence of asymptomatic optic nerve lesions

Renaud Lopes, X. Leclerc, O. Outteryck, 2022, Journal of Neurology.

A Fully Automatic Method for Optic Radiation Tractography Applicable to Multiple Sclerosis Patients

J. Pruvo, Renaud Lopes, J. Dumont, 2020, Brain Topography.

Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal

P. Vermersch, M. Cambron, P. Labauge, 2016, Journal of Neurology.

Comparison of biomarker for diagnosis of nitrous oxide abuse: challenge of cobalamin metabolic parameters, a retrospective study

C. Tard, D. Dobbelaere, P. Pigny, 2023, Journal of Neurology.

Heterogeneity of cognitive impairments in myotonic dystrophy type 1 explained by three distinct cognitive profiles.

C. Tard, Loren Fragoso, Amina Wilu-Wilu, 2024, Journal of neurology.